Cost-utility analysis of R-CHOP vs CHOP in patients with non-hodgkin's lymphoma: a systematic review

Background: Non-Hodgkin Lymphoma (NHL) ranks 11th in cancer incidence and mortality in the Philippines with the combination chemotherapy composed of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) being commonly used as treatment. However, the addition of Rituximab to CHOP (R-CHOP)...

Full description

Bibliographic Details
Main Author:	Cadag, Camille Francesca T. (Author)
Other Authors:	Lorenzo, Althea B. (author .), Mercado, Justine Marie M. (author .), Ngo, Frances Lois U. (adviser .)
Format:	Thesis
Language:	English
Subjects:	Cost effectiveness > Lymphoma--therapy > Comparative effectiveness research. Non-Hodgkin’s Lymphoma, . R-CHOP. CHOP. Rituximab. Cost-utility. Economic evaluation.